ReAlta Life Sciences’ RLS-0071 Gains the US FDA’s ODD & FTD to Treat Steroid-Refractory aGvHD
Shots:
- The US FDA has granted Orphan Drug Designation (ODD) & Fast Track Designation (FTD) to the company’s RLS-0071 for treating steroid-refractory acute graft-versus-host disease (aGvHD) in hospitalized individuals.
- RLS-0071 is presently an ongoing P-II open-label study for treating hospitalized individuals who have steroid-refractory aGvHD
- Additionally, the company is presently carrying out a P-II study for RLS-0071 in newborns suffering from hypoxic-ischemic encephalopathy (HIE) and in hospitalized individuals experiencing acute exacerbations of chronic obstructive pulmonary disease.
Ref: ReAlta Life Sciences | Image: ReAlta Life Sciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
